Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study

被引：0
|
作者：
Oh, D-Y. [1 ]
Meric-Bernstam, F. [2 ]
Makker, V. [3 ]
Oaknin, A. [4 ]
Banerjee, S. [5 ]
Gonzalez Martin, A. [6 ,7 ]
Jung, K. H. [8 ]
Lugowska, I. [9 ,10 ]
Manso, L. M. [11 ]
Manzano, A. [12 ]
Melichar, B. [13 ]
Siena, S. [14 ]
Stroyakovskiy, D. [15 ]
Fielding, A. [16 ]
Ma, Y. [17 ]
Puvvada, S. D.
Lee, J-Y. [18 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Vall dHebron Inst Oncol, Hosp Univ Vall dHebron, Gynaecol Canc Programme, Barcelona, Spain
[5] Royal Marsden NHS Fdn Trust & Inst Canc Res, Gynaecol Unit, London, England
[6] Univ Navarra, Canc Ctr Clin, Med Oncol Dept, Madrid, Spain
[7] Univ Navarra, Canc Ctr Clin, Programme Solid Tumours CIMA, Madrid, Spain
[8] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[9] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Early Phase Clin Trials Unit, Warsaw, Poland
[10] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[11] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[12] Hosp Clin San Carlos, Dept Med Oncol, Expt Therapeut Canc UTEC, Madrid, Spain
[13] Palacky Univ, Univ Hosp, Dept Oncol, Med Sch, Olomouc, Czech Republic
[14] Univ Milan, Dept Oncol, Piazza Osped Maggiore, Milan, Italy
[15] Moscow City Oncol Hosp 62, Healthcare Dept, Moscow, Russia
[16] AstraZeneca, Oncol R&D, Gaithersburg, MD USA
[17] AstraZeneca, Oncol R&D, Cambridge, England
[18] Yonsei Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
74MO
引用
收藏
页码：S1494 / S1495
页数：2
相关论文
共 50 条
  • [31] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
    Siena, S.
    Raghav, K.
    Masuishi, T.
    Yamaguchi, K.
    Nishina, T.
    Elez, E.
    Rodriguez, J.
    Chau, I.
    Di Bartolomeo, M.
    Kawakami, H.
    Suto, F.
    Kobayashi, K.
    Koga, M.
    Inaki, K.
    Kuwahara, Y.
    Takehara, I.
    Grothey, A.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S532 - S532
  • [33] Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours
    Takahashi, M.
    Bang, Y-J.
    Karayama, M.
    Watanabe, J.
    Minami, H.
    Yamamoto, N.
    Kinoshita, I.
    Lin, C. C.
    Im, Y-H.
    Fujiki, T.
    Achiwa, I.
    Kamiyama, E.
    Okuda, Y.
    Lee, C.
    Takahashi, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S68 - S69
  • [34] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01
    Yoshino, T.
    Siena, S.
    Di Bartolomeo, M.
    Raghav, K.
    Masuishi, T.
    Loupakis, F.
    Kawakami, H.
    Yamaguchi, K.
    Nishina, T.
    Fakih, M.
    Elez, E.
    Rodriguez, J.
    Ciardiello, F.
    Saxena, K.
    Yamamoto, E.
    Kobayashi, K.
    Bako, E.
    Okuda, Y.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1275 - S1275
  • [35] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
    Ohba, Akihiro
    Morizane, Chigusa
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ueno, Makoto
    Kobayashi, Satoshi
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Furuse, Junji
    Okano, Naohiro
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Sadachi, Ryo
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
    Hamilton, E. P.
    Shapiro, C. L.
    Boni, V.
    Jimenez, M. Martin
    Del Conte, G.
    Cortes, J.
    Agrawal, L.
    Arkenau, H-T.
    Tan, A. R.
    Debruyne, P. R.
    Minchom, A. R.
    Rutten, A.
    Valdes-Albini, F.
    Yu, E.
    Suto, F.
    Cheng, F-C.
    Augustine, B.
    Cheng, B.
    Barrios, D.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S196 - S196
  • [37] Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
    Galsky, Matt D.
    Del Conte, Gianluca
    Foti, Silvia
    Yu, Evan Y.
    Machiels, Jean-Pascal H.
    Doger, Bernard
    Necchi, Andrea
    De Braud, Filippo G.
    Hamilton, Erika P.
    Hennequin, Audrey
    Van den Mooter, Tom
    Debruyne, Philip R.
    Moreno, Irene
    Arkenau, Hendrik-Tobias
    Tsuchihashi, Zenta
    Cheng, Fu-Chih
    Augustine, Bincy
    Cheng, Ben
    Barrios, Daniel
    Luftner, Diana
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
    Li, B. T.
    Planchard, D.
    Goto, K.
    Smit, E. F.
    De langen, J.
    Goto, Y.
    Ninomiya, K.
    Kubo, T.
    Perol, M.
    Felip, E.
    Hayashi, H.
    Nakagawa, K.
    Shimizu, J.
    Nagasaka, M.
    Pereira, K. M. C.
    Taguchi, A.
    Ali, A.
    Karnoub, M.
    Yonemochi, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34
  • [39] Updated analysis of DESTINY-Gastric02: A phase II singlearm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/ metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
    Ku, G. Y.
    Di Bartolomeo, M.
    Smyth, E.
    Chau, I.
    Park, H.
    Siena, S.
    Lonardi, S.
    Wainberg, Z. A.
    Ajani, J. A.
    Chao, J.
    Barlaskar, F.
    Kawaguchi, Y.
    Qin, A.
    Singh, J.
    Meinhardt, G.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1100 - S1100
  • [40] Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
    Bartsch, R.
    Berghoff, A. S.
    Furtner, J.
    Marhold, M.
    Bergen, E. S.
    Roider-Schur, S.
    Starzer, A. M.
    Forstner, H.
    Rottenmanner, B.
    Dieckmann, K.
    Bago-Horvath, Z. A.
    Widhalm, G.
    Ilhan-Mutlu, A.
    Minichsdorfer, C.
    Fuereder, T.
    Singer, C. F.
    Weltermann, A.
    Puhr, R.
    Preusser, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S198 - S198
12345